Dr. Laith I. Abushahin, MBBS
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 329
Licensed in Texas since 2022, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license T9620 (first issued 2022; active) · IA license 40874 · OH license 35.133806 -
Internal Medicine Physician
IA license 40874
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor University Medical Center Dallas, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 329
- Services billed
- 58,971
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, fosaprepitant, 1 mg | 7,050 | 38 |
| Injection, pembrolizumab, 1 mg | 6,200 | 24 |
| Injection, paclitaxel, 1 mg | 3,498 | 16 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,664 | 17 |
| Injection, dexamethasone sodium phosphate, 1 mg | 898 | 63 |
| Injection, palonosetron hcl, 25 mcg | 550 | 43 |
| Injection, granisetron hydrochloride, 100 mcg | 270 | 18 |
| Blood test, comprehensive group of blood chemicals | 264 | 70 |
| Insertion of needle into vein for collection of blood sample | 256 | 67 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 253 | 64 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Dallas, TX | 18 |
| Prochlorperazine Maleate Other prescribers in Dallas, TX | 17 |
| Tramadol Hcl Other prescribers in Dallas, TX | 17 |
| Oxycodone Hcl Other prescribers in Dallas, TX | 13 |
| Imatinib Mesylate | 12 |
| Duloxetine Hcl Other prescribers in Dallas, TX | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 44 payments worth $36,992 in total to this clinician.
| Ipsen Biopharmaceuticals, Inc | $25,604 |
|---|---|
| Springworks Therapeutics, Inc. | $6,842 |
| Amgen Inc. | $4,323 |
| AbbVie Inc. | $172 |
| Merck Sharp & Dohme LLC | $30.09 |
| Tempus Ai, Inc | $22.06 |
| Compensation for services other than consulting (speaking, faculty) | $32,865 |
|---|---|
| Travel and Lodging | $3,346 |
| Food and Beverage | $781 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc May 7, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde · Oncology | $6,248 |
| Ipsen Biopharmaceuticals, Inc Nov 8, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde · Oncology | $6,248 |
| Ipsen Biopharmaceuticals, Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde · Oncology | $4,778 |
| Amgen Inc. Sep 16, 2025 | Compensation for services other than consulting (speaking, faculty) VECTIBIX · Oncology | $3,600 |
| Ipsen Biopharmaceuticals, Inc Feb 12, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde · Oncology | $2,573 |
| Ipsen Biopharmaceuticals, Inc Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde · Oncology | $2,205 |
| Springworks Therapeutics, Inc. Jan 23, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $2,025 |
| Springworks Therapeutics, Inc. Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $2,025 |
| Springworks Therapeutics, Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $2,025 |
| Ipsen Biopharmaceuticals, Inc Oct 10, 2025 | Travel and Lodging Onivyde · Oncology · travel to San Antonio, TX · in-kind | $703 |
All 18 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc Nov 8, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde · Oncology | $6,248 |
| Ipsen Biopharmaceuticals, Inc Nov 8, 2025 | Travel and Lodging Onivyde · Oncology · travel to Seattle, WA · in-kind | $693 |
| Ipsen Biopharmaceuticals, Inc Nov 8, 2025 | Travel and Lodging Onivyde · Oncology · travel to Seattle, WA · in-kind | $382 |
| Ipsen Biopharmaceuticals, Inc Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde · Oncology | $2,205 |
| Ipsen Biopharmaceuticals, Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde · Oncology | $4,778 |
| Ipsen Biopharmaceuticals, Inc Oct 10, 2025 | Travel and Lodging Onivyde · Oncology · travel to San Antonio, TX · in-kind | $703 |
| Ipsen Biopharmaceuticals, Inc Oct 10, 2025 | Travel and Lodging Onivyde · Oncology · travel to San Antonio, TX · in-kind | $166 |
| Amgen Inc. Sep 16, 2025 | Compensation for services other than consulting (speaking, faculty) VECTIBIX · Oncology | $3,600 |
| Amgen Inc. Sep 16, 2025 | Compensation for services other than consulting (speaking, faculty) VECTIBIX · Oncology | $600 |
| Ipsen Biopharmaceuticals, Inc May 7, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde · Oncology | $6,248 |
| Ipsen Biopharmaceuticals, Inc May 7, 2025 | Travel and Lodging Onivyde · Oncology · travel to Virginia Beach, VA · in-kind | $638 |
| Ipsen Biopharmaceuticals, Inc May 7, 2025 | Travel and Lodging Onivyde · Oncology · travel to Virginia Beach, VA · in-kind | $449 |
| Springworks Therapeutics, Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $540 |
| Springworks Therapeutics, Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $2,025 |
| Springworks Therapeutics, Inc. Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $2,025 |
| Ipsen Biopharmaceuticals, Inc Feb 12, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde · Oncology | $2,573 |
| Ipsen Biopharmaceuticals, Inc Feb 12, 2025 | Travel and Lodging Onivyde · Oncology · travel to Dallas, TX · in-kind | $315 |
| Springworks Therapeutics, Inc. Jan 23, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $2,025 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $233,709 in research payments for these studies, mostly to the institutions running them.
- A Phase III,Randomized,Double Blind,Placebo Controlled,Multicenter,Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment in Adult Participants After Resection of Biliary Tract Cancer wit…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.